FTC opens investigation into largest PBMs' anticompetitive practices
The Federal Trade Commission is turning up the heat on the drug industry’s middlemen, launching an investigation into pharmacy benefit manager practices and the effect on drug prices. The move comes just a few months after a different study proposal failed to gain enough support among the FTC commissioners in a 2-2 tie vote.
Now with a revamped study and newly appointed President Biden pick Alvaro Bedoya on board, the commission voted unanimously 5-0 to dig into PBM practices.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.